Diskussion zur BICO Group Aktie WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Hedgehog3

Ja, sorry.

Fehlt da ein „gibt“?

Ist ein Zitat. Eine Überlegung wert.

 Von allen Fehlern beim Spekulieren es nur wenige, die größer sind als der Versuch, Verluste zu verbilligen durch Nachkäufe.

hab den newsletter von Bico abonniert, würde ich auch allen empfehlen, dann bekommt man direkt die neusten Infos per mail :-)

Mirkinho, Danke für die Info.👍

20 er kippt auch noch🥶

Besser vorsicht…. Fällt ja wieder…

Weil??

Jetzt kaufen Leute. Die Gelegenheit schlechthin

also wenn an über 100 Millionen Tieren jedes Jahr getestet wird, ist das auf jeden Fall kein kleiner Markt...

BICO Partners with the Center for Contemporary Sciences to Reduce Animal Testing in Life Sciences The two organizations will work closely to build support for the bipartisan FDA Modernization Act and reduce animal testing by promoting human-specific medical research technologies that include advanced in-vitro tissue models and 3D bioprinting. Today BICO, a leading bio convergence company, announced a partnership with the Center for Contemporary Sciences (CCS), a research and advocacy organization championing the advancement of human-relevant methodologies in scientific research and drug discovery. Together the two organizations plan to closely align strategy and outreach efforts to support the passage of the bipartisan FDA Modernization Act of 2021, along with other initiatives to reduce animal testing in the life sciences industry. The FDA Modernization Act would amend the 1938 Federal Food, Drug, and Cosmetic Act legislation that requires all new pharmaceuticals be tested on animals for safety and efficacy, regardless of whether such tests are predictive or relevant to outcomes in humans. With more than 80 years in existence, this regulation contributes to an estimated 100 million animals being experimented on each year for biomedical research in the U.S. alone, at least 90% failure rate in human clinical trials, and a staggering cost in the development of new pharmaceutical drugs, which is typically passed onto consumers. One of the main goals of the partnership is to promote bio convergence technologies to accelerate human-relevant drug development and other applications, without experimentation on animals. Such technologies include advanced in-vitro tissue models, 3D bioprinting, organs-on-a-chip, and sophisticated microfluidics platforms. “The Center for Contemporary Sciences will be a key ally in our efforts to help pass the FDA Modernization Act,” says Erik Gatenholm, CEO and co-founder at BICO. “Aysha and her team bring decades of experience in science, medicine, and policy to help develop and advance human-relevant technologies that drive positive change in the industry.” The Center for Contemporary Sciences’ goal is to educate, connect, and support the scientific research industry with modern innovations but also replace experimental animal testing. With a science-driven mission that recognizes that animal models are not translatable to human biology, CCS places emphasis on human-relevant methods that currently exist or can be developed, to provide a more accurate human response and bring safer, more efficacious therapies to market for the benefit of patients. "The partnership with, BICO, one of the most exciting and credible bio convergence forces in the industry today reflects our commitment to work alongside like-minded organizations to modernize the drug development process through dedicated advocacy efforts and discerning policies rooted in evidence-based science,” says CCS Chief Science Officer, Zaher Nahle, PhD, MPA. “It is also a realization of the vison of CCS co-founder and CEO, Aysha Akhtar MD, MPH and the Board, to bring real change to a process that has been woefully neglected for far too long, and that would save both human and animal lives.” The partnership also comes a month after CCS partnered with MatTek, a BICO company and leading developer of in-vitro human tissue models widely used in the drug-, cosmetic-, and chemical industries to replace animal testing.

Nochmals. Hebt die Fed an und die EU nicht, werden die Rohstoffe teurer, was sich auf Herstellung und Logistik auswirkt. Hebt die EU den Zins an, werden die Kredite teurer, was bei einem gut verschuldeten Unternehmen ggf. Zu Problemen führen kann. Bleibt zu hoffen, dass die FED die Zinsen nicht zu stark anhebt und die globalen Lieferketten wieder effizient laufen.

Drei Zinsschritte und eine deutliche Inflation sind gefühlt eingepreist. Starke Bewegung nach unten erwarte ich im Gesamtmarkt nur wenn es negative Entwicklungen gibt die keiner vorhersagen kann (Eskalation China/USA, Corona Mutante XY usw.)

Ehrlich gesagt glaube ich mit einem Anstieg des Zinsniveau und einer Inflation von 5% Plus werden Wachstumswerte wie Bico nochmal richtig rasiert. Bin zeitnah mit ner kleinen Posi dabei, aber denke es rutscht noch deutlich weiter ab.